Allworth Financial
RAPP icon

Allworth Financial’s Rapport Therapeutics RAPP Stock Holding History

Allworth Financial’s Portfolio RAPP Stock Details RAPP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$292 Hold
7
– – ﹤0.01% 5025
2026
Q2 		$292 Buy
7
+3
+75% +$110 ﹤0.01% 4915
2026
Q1 		$126 Buy
+4
New +$113 ﹤0.01% 4986
2025
Q2 		– Sell
-15
Closed -$167 – 4686
2025
Q1 		$167 Buy
+15
New +$195 ﹤0.01% 3905

Other funds holding RAPP

Johnson & Johnson
Johnson & Johnson New Brunswick, New Jersey $762M AUM 69.66% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Candriam SCA
Candriam SCA Strassen, Luxembourg, Luxembourg $22.5B AUM 50.38% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $118B AUM 40.52% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
ALPS Advisors
ALPS Advisors Denver, Colorado $21.8B AUM 17.58% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 33.83% 1-Year Est. Return
Profund Advisors
Profund Advisors Bethesda, Maryland $3.48B AUM 66.96% 1-Year Est. Return
Sigma Planning Corp
Sigma Planning Corp Ann Arbor, Michigan $3.88B AUM 23.38% 1-Year Est. Return

Allworth Financial's RAPP Position: Q3 2026 in Review

Allworth Financial held its Rapport Therapeutics (RAPP) position steady in Q3 2026 at 7 shares worth $292. The position accounts for ﹤0.01% of the portfolio, ranked #5025.

Allworth Financial first reported a position in RAPP in Q1 2025 and has held it in 4 quarters since. 51 funds tracked by Wall St. Rank hold RAPP as of Q3 2026.

  • Allworth Financial held 7 shares of Rapport Therapeutics worth $292 as of Q3 2026.
  • Allworth Financial left its Rapport Therapeutics share count unchanged in Q3 2026.
  • Rapport Therapeutics made up ﹤0.01% of Allworth Financial's portfolio in Q3 2026, its #5025 holding.
  • Allworth Financial first reported a position in Rapport Therapeutics in Q1 2025 and has held it in 4 quarters since.
  • 51 funds tracked by Wall St. Rank held Rapport Therapeutics as of Q3 2026.

Based on Allworth Financial's 13F filing for Q3 2026, filed 6 Nov 2026.